Display options
Cite
Trinh AT, Ball BG, Weber E, et al. Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression. Genet Vaccines Ther. 2009;7:13doi: 10.1186/1479-0556-7-13.
Trinh, A. T., Ball, B. G., Weber, E., Gallaher, T. K., Gluzman-Poltorak, Z., Anderson, F., & Basile, L. A. (2009). Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression. Genetic vaccines and therapy, 713. https://doi.org/10.1186/1479-0556-7-13
Trinh, Alice T, et al. "Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression." Genetic vaccines and therapy vol. 7 (2009): 13. doi: https://doi.org/10.1186/1479-0556-7-13
Trinh AT, Ball BG, Weber E, Gallaher TK, Gluzman-Poltorak Z, Anderson F, Basile LA. Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression. Genet Vaccines Ther. 2009 Dec 30;7:13. doi: 10.1186/1479-0556-7-13. PMID: 20042112; PMCID: PMC2809042.
Copy Download .nbib Format: NLM
Share it on

Genet Vaccines Ther. 2009 Dec 30;7:13. doi: 10.1186/1479-0556-7-13.

Retroviral vectors encoding ADA regulatory locus control region provide enhanced T-cell-specific transgene expression.

Genetic vaccines and therapy

Alice T Trinh, Bret G Ball, Erin Weber, Timothy K Gallaher, Zoya Gluzman-Poltorak, French Anderson, Lena A Basile

Affiliations

  1. Neumedicines Inc, Pasadena, California 91107, USA. [email protected]

PMID: 20042112 PMCID: PMC2809042 DOI: 10.1186/1479-0556-7-13

Abstract

BACKGROUND: Murine retroviral vectors have been used in several hundred gene therapy clinical trials, but have fallen out of favor for a number of reasons. One issue is that gene expression from viral or internal promoters is highly variable and essentially unregulated. Moreover, with retroviral vectors, gene expression is usually silenced over time. Mammalian genes, in contrast, are characterized by highly regulated, precise levels of expression in both a temporal and a cell-specific manner. To ascertain if recapitulation of endogenous adenosine deaminase (ADA) expression can be achieved in a vector construct we created a new series of Moloney murine leukemia virus (MuLV) based retroviral vector that carry human regulatory elements including combinations of the ADA promoter, the ADA locus control region (LCR), ADA introns and human polyadenylation sequences in a self-inactivating vector backbone.

METHODS: A MuLV-based retroviral vector with a self-inactivating (SIN) backbone, the phosphoglycerate kinase promoter (PGK) and the enhanced green fluorescent protein (eGFP), as a reporter gene, was generated. Subsequent vectors were constructed from this basic vector by deletion or addition of certain elements. The added elements that were assessed are the human ADA promoter, human ADA locus control region (LCR), introns 7, 8, and 11 from the human ADA gene, and human growth hormone polyadenylation signal. Retroviral vector particles were produced by transient three-plasmid transfection of 293T cells. Retroviral vectors encoding eGFP were titered by transducing 293A cells, and then the proportion of GFP-positive cells was determined using fluorescence-activated cell sorting (FACS). Non T-cell and T-cell lines were transduced at a multiplicity of infection (MOI) of 0.1 and the yield of eGFP transgene expression was evaluated by FACS analysis using mean fluorescent intensity (MFI) detection.

RESULTS: Vectors that contained the ADA LCR were preferentially expressed in T-cell lines. Further improvements in T-cell specific gene expression were observed with the incorporation of additional cis-regulatory elements, such as a human polyadenylation signal and intron 7 from the human ADA gene.

CONCLUSION: These studies suggest that the combination of an authentically regulated ADA gene in a murine retroviral vector, together with additional locus-specific regulatory refinements, will yield a vector with a safer profile and greater efficacy in terms of high-level, therapeutic, regulated gene expression for the treatment of ADA-deficient severe combined immunodeficiency.

References

  1. Pediatr Clin North Am. 2002 Oct;49(5):989-1007 - PubMed
  2. Blood. 2004 Oct 15;104(8):2281-90 - PubMed
  3. J Clin Invest. 2007 Aug;117(8):2083-6 - PubMed
  4. Blood. 2008 May 1;111(9):4431-44 - PubMed
  5. J Virol. 2000 May;74(10):4679-87 - PubMed
  6. J Clin Invest. 2007 Aug;117(8):2241-9 - PubMed
  7. J Clin Invest. 2004 Oct;114(7):953-62 - PubMed
  8. Nat Med. 1995 Oct;1(10):1017-23 - PubMed
  9. Blood. 2000 Aug 1;96(3):894-901 - PubMed
  10. Genes Dev. 1989 Sep;3(9):1384-400 - PubMed
  11. Science. 2000 Apr 28;288(5466):669-72 - PubMed
  12. Mol Cell Biol. 2006 Sep;26(18):6832-43 - PubMed
  13. Nucleic Acids Res. 1995 Feb 25;23(4):628-33 - PubMed
  14. N Engl J Med. 2009 Jan 29;360(5):447-58 - PubMed
  15. Blood. 2003 Mar 15;101(6):2099-114 - PubMed
  16. J Virol. 2005 Mar;79(6):3627-38 - PubMed
  17. Blood. 2003 Dec 15;102(13):4312-9 - PubMed
  18. Blood. 2003 Jun 15;101(12):4717-24 - PubMed
  19. Proc Natl Acad Sci U S A. 1986 May;83(10):3194-8 - PubMed
  20. Science. 1998 Jul 3;281(5373):60-3 - PubMed
  21. J Virol. 1998 Feb;72(2):1632-9 - PubMed
  22. Pediatr Res. 1993 Jan;33(1 Suppl):S42-7; discussion S47-8 - PubMed
  23. J Hematother Stem Cell Res. 2002 Jun;11(3):449-56 - PubMed
  24. Biochemistry. 1986 Dec 16;25(25):8234-44 - PubMed
  25. Pharmacogenomics. 2008 Jul;9(7):947-68 - PubMed
  26. Blood. 2002 Sep 15;100(6):2012-9 - PubMed
  27. Hum Gene Ther. 1994 Jan;5(1):19-28 - PubMed
  28. J Virol. 1997 Nov;71(11):8103-8 - PubMed
  29. Clin Genet. 2001 Jan;59(1):17-24 - PubMed
  30. Blood. 2003 Feb 15;101(4):1284-9 - PubMed
  31. Exp Hematol. 2004 May;32(5):461-9 - PubMed
  32. Cell. 2004 Sep 3;118(5):555-66 - PubMed
  33. Hum Gene Ther. 2001 Mar 1;12(4):323-32 - PubMed
  34. J Virol. 2000 Mar;74(5):2365-71 - PubMed
  35. Blood. 2000 Nov 1;96(9):3016-22 - PubMed
  36. Genes Dev. 2007 Dec 1;21(23):3027-43 - PubMed
  37. Blood. 2004 Jun 1;103(11):4062-9 - PubMed
  38. Nature. 1999 Mar 25;398(6725):344-8 - PubMed
  39. Hum Mutat. 1995;5(2):107-12 - PubMed
  40. Blood. 2003 Apr 15;101(8):2932-9 - PubMed
  41. N Engl J Med. 2004 Feb 26;350(9):913-22 - PubMed
  42. Cell. 1986 Nov 7;47(3):391-9 - PubMed
  43. Science. 1995 Oct 20;270(5235):475-80 - PubMed
  44. Science. 1995 Oct 20;270(5235):470-5 - PubMed

Publication Types